Compare BridgeBio Pharma Inc (BBIO) vs Microsoft (MSFT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Microsoft — how do they compare? BridgeBio Pharma Inc trades at $84.09 (market cap $16.27B), while Microsoft trades at $386.66 (market cap $2.90T). The key difference: Microsoft is far larger — about 178.2× BridgeBio Pharma Inc's market cap, and Microsoft pays a 0.93% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | MSFT | |
|---|---|---|
Market Cap | $16.27B | $2.90T |
Sector | Health | Technology |
52-Week High | $90.17 | $542.07 |
52-Week Low | $44.81 | $352.83 |
Enterprise Value | $17.82B | $2.88T |
Volume | — | 36,654,621 |
Dividend Yield | — | 0.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Microsoft (MSFT) trades at $390.99, up 1.53% today, with a neutral technical signal and strong fundamental performance. The company reported consistent earnings beats in recent quarters, with Q1 2026 EPS of $4.27 exceeding the $4.06 estimate. Revenue growth remains robust at $281.72B for 2025, supported by 68.31% gross margins and $136.16B in operating cash flow. Analyst consensus is overwhelmingly bullish with 80.49% buy ratings and a $552.81 price target, representing 41% upside potential from current levels.
Microsoft's AI leadership and cloud momentum position it for continued growth, though elevated capital expenditures and competitive pressures present near-term headwinds. The stock's current valuation at 23.29 P/E appears reasonable given the company's strong profitability and growth trajectory. Institutional ownership remains substantial, with recent news highlighting Azure's strength and Copilot adoption as key catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Microsoft
Microsoft Corporation develops, manufactures, licenses, sells, and supports software products. The Company offers operating system software, server application software, business and consumer applications software, software development tools, and Internet and intranet software. Microsoft also develops video game consoles and digital music entertainment devices.
Read more on MSFT →
